CN102743448A - Compound traditional Chinese medicine for treating hyperlipidemia - Google Patents
Compound traditional Chinese medicine for treating hyperlipidemia Download PDFInfo
- Publication number
- CN102743448A CN102743448A CN2012102090573A CN201210209057A CN102743448A CN 102743448 A CN102743448 A CN 102743448A CN 2012102090573 A CN2012102090573 A CN 2012102090573A CN 201210209057 A CN201210209057 A CN 201210209057A CN 102743448 A CN102743448 A CN 102743448A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- traditional chinese
- polygoni multiflori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a compound traditional Chinese medicine for treating hyperlipidemia, and belongs to the technical field of Chinese herbal medicine. The compound traditional Chinese medicine is prepared by the following raw material herbs by weight: 6-15 parts of pseudo-ginseng; 3-10 parts of kudzu roots; 3-10 parts of cassia seeds; 6-12 parts of polygonum multiflorum; and 1-5 parts of cortex cinnamomi. The compound medicament has refined composition, and can be developed into compound traditional Chinese medicines with various dosage forms so as to be convenient for patient administration. The composition herbs of the invention are listed in 'List of substances which are both food and medicine' and 'List of substances which can be used in health food' published by the ministry of health, and the compound traditional Chinese medicine of the invention can be developed into health products for lipid lowering assistance.
Description
Technical field
The present invention relates to a kind of herbal mixture that is used to treat hyperlipemia, belong to field of Chinese herbal medicine technology.
Background technology
Blood fat is neutral fat (triglyceride and cholesterol) and the general name of lipoid (phospholipid, glycolipid, sterin, steroid) in the blood plasma, extensively is present in the human body, and be the essential material of life cells basal metabolism.Main Ingredients and Appearance in the blood fat is triglyceride and cholesterol, wherein triglyceride participant energy i (in vivo) metabolism, and cholesterol then is mainly used in synthetic cell serous coat, steroid hormone and bile acid.Blood fat just can be dissolved in blood plasma and transport metabolism after combining with apolipoprotein to form lipoprotein.Lipoprotein is divided into Chylomicron (CM), VLDL (VLDL), low density lipoprotein, LDL (LDL), high density lipoprotein (HDL).Various lipoproteins have substantially invariable concentration in blood plasma.The variation of blood fat is the interior metabolic situation of lipid of antimer basically.
Hyperlipemia (Hyperlipidemia; HLP) be dyslipidemia (dysllpidemnia) again; Be the abbreviation of blood lipid Developmental and Metabolic Disorder, it mainly refer to T-CHOL in the blood (total cholesterol, TC), triglyceride (triglyceride; TG) and low-density lipoprotein cholesterol (low density lipoprotein cholesterol; LDL-C) level is too high, and blood middle-high density lipoprotein cholesterol (high density lipoprotein cholesterol, HDL-C) level is low excessively.In recent years, the Along with people's living standard improves constantly, the change and the momental minimizing of dietary structure and life style, and the sickness rate of hyperlipemia is in continuous increase.Existing research shows that lipid metabolic disorder is the important risk factor of bringing out diseases such as atherosclerosis, coronary heart disease, myocardial infarction, cerebral thrombosis, fatty liver, diabetes, pancreatitis due to hyperlipidemia in the serum.
Chinese medicine thinks that hyperlipemia belongs to qi-blood-body fluid pathological changes category, and cards such as, blood stasis turbid with expectorant are similar, is to be basis with liver,spleen,kidney three dirty void, and expectorant is turbid, blood is the target disease.May be summarized to be dysfunction of the spleen in transportation, give birth in the phlegm-damp; The folding of suffering from a deficiency of the kidney is unfavorable, retention of water-damp in the body; Depression of liver-QI, qi depression to blood stasis; The phlegm-damp blood stasis, the venation of being detained; Deficiency in origin and excess in superficiality, simulataneous insufficiency and excessive.Though the primary disease pathogenesis is intricate, outer void, expectorant, the stasis of blood, stagnant four.Invigorating the spleen and benefiting QI is mainly used in the Chinese traditional treatment of hyperlipemia, the eliminating phlegm blood stasis dispelling; Soothing liver and strengthening spleen, eliminate stagnation and dissolve phlegm; Nourishing the liver and kidney, methods such as benefiting QI for activating blood circulation.These methods derive from the clinical syndrome differentiation opinion of hyperlipemia and control, though have clinical specific aim, prescription is fixing, are a kind of obstacles for the development and application of medicine, more are unfavorable for serving extensive patients.
Summary of the invention
The object of the present invention is to provide a kind of herbal mixture with treatment hyperlipemia of significant curative effect.This medicament composing prescription is clear and definite, and is evident in efficacy definite, is the traditional Chinese medical science prescription of inventor through obtaining after the clinical verification.
A kind of herbal mixture medicine of treating hyperlipemia of the present invention, process by the crude drug of following parts by weight:
6-15 part; Radix Puerariae 3-10 part; Semen Cassiae 3-10 part; Radix Polygoni Multiflori 6-12 part; Cortex Cinnamomi 1-5 part;
The weight ratio of medicine material medicine of the present invention is preferably:
Radix Notoginseng 6-12 part; Radix Puerariae 3-8 part; Semen Cassiae 4-7 part; Radix Polygoni Multiflori 6-12 part; Cortex Cinnamomi 1-2 part;
The weight ratio of crude drug is more preferably in the Chinese medicine composition of the present invention:
6 parts of Radix Notoginseng; 3 parts of Radix Puerariaes; 4 parts of Semen Cassiaes; 6 parts of Radix Polygoni Multiflori; 1 part of Cortex Cinnamomi;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
12 parts of Radix Notoginseng; 8 parts of Radix Puerariaes; 7 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 2 parts of Cortex Cinnamomis;
The weight ratio of crude drug is more preferably in the Chinese medicine composition of the present invention:
12 parts of Radix Notoginseng; 6 parts of Radix Puerariaes; 6 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 2 parts of Cortex Cinnamomis;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
15 parts of Radix Notoginseng; 8 parts of Radix Puerariaes; 8 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 2 parts of Cortex Cinnamomis;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
15 parts of Radix Notoginseng; 9 parts of Radix Puerariaes; 9 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 4 parts of Cortex Cinnamomis;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
12 parts of Radix Notoginseng; 8 parts of Radix Puerariaes; 8 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 4 parts of Cortex Cinnamomis;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
15 parts of Radix Notoginseng; 10 parts of Radix Puerariaes; 10 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 5 parts of Cortex Cinnamomis;
Pharmaceutical dosage form of the present invention is a kind of in powder, pill, capsule, tablet, granule, oral liquid, the decoction; For realizing above-mentioned dosage form; Need in the preparation process, to add corresponding pharmacy adjuvant, like filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc.
The consumption of composition of medicine among the present invention by the crude drug total weight of Chinese medicinal components of performance therapeutical effect, is 30-55 gram every day, every day 1 time or divide and take for 2 times.
Advantage of the present invention: this compound medicine is formed refine, and the herbal mixture that can be developed into multiple dosage form facilitates patients.Among " be food be again the article list of medicine " that this prescription medicine lists all that Ministry of Public Health announces in, " the article list that can be used for health food ", also can be developed into health product, be used for assistant lipid-lowering.
The specific embodiment
Radix Notoginseng has another name called Radix Notoginseng, is araliaceae ginseng plant's dry root.Sweet in the mouth, little hardship, warm in nature, have the dissipating blood stasis hemostasis, effects such as subduing swelling and relieving pain are the drug for invigorating blood circulation and eliminating stasis of using always, are widely used in the treatment of cardiovascular disease.Recent study finds that Radix Notoginseng can pass through link prevention and antagonism thrombosiss such as antiplatelet aggregation, antithrombase and promotion fibrinolysis, reduces the blood plasma viscosity.Radix Notoginseng total arasaponins has activating blood circulation to dissipate blood stasis, it is active to promote blood circulation, the effect of anticoagulant, microcirculation improvement; Can reduce the content of serum total cholesterol, triglyceride, low density lipoprotein, LDL; And reduction blood plasma viscosity, blood viscosity and hematocrit; Thereby effectively control hyperlipemia and high blood viscosity, the generation of prevention cardiovascular and cerebrovascular disease.
Radix Puerariae is the dry root of legume pueraria lobata or Radix Puerariae rattan, is clinical commonly used drug.In Shennong's Herbal, have record to Radix Puerariae, its " sweet in the mouth, flat.Cure mainly and quench one's thirst, high fever of the body, vomiting, all numbness plays cloudy gas, separates all poison ".At present, Radix Puerariae has been widely used in cardiovascular disease and endocrine metabolism property treatment of diseases, and blood lipid regulation mainly one of is used for it.Modern pharmacological research shows that osajin compositions such as the puerarin in the Radix Puerariae, daiazi, daidzein, genistin all have resisting myocardial ischemia, expand cardiovascular system pharmacology activity such as blood vessel, blood fat reducing.Wherein, puerarin can obviously reduce the mice serum total cholesterol level, and high density lipoprotein increasing content reduces low density lipoprotein, LDL and VLDL content, prevents the low density lipoprotein, LDL over oxidation.Puerarin reduces fat in the coronary arterial wall deposition through above effect, thereby reduces atherosclerotic incidence rate.
Semen Cassiae is the dry mature seed of leguminous plant Semen Cassiae, and is cold in nature, and sweet-bitter flavor has effects such as liver heat removing and eyesight improving, diuretic, relieving constipation.Modern pharmacological research shows; Pharmacological evaluation and clinical observation prove that Semen Cassiae can reduce serum total cholesterol and triglyceride levels, anticoagulant; Can also obviously raise serum high-density LP content and improve HDL-C/TC ratio of Semen Cassiae; Obviously improve the distribution situation of body inner cholesterol, delay to reverse the formation of atheromatous plaque, thereby obviously reduce the M & M of cardiovascular disease with part.
Radix Polygoni Multiflori is the dried root of polygonum multiflorum thunb, and its nature and flavor are bitter, sweet, puckery, warm, has effects such as invigorating the liver and kidney, benefiting essence-blood, loosening bowel to relieve constipation.Modern pharmacological research shows that Radix Polygoni Multiflori and extract thereof can significantly reduce serum total cholesterol and content of triglyceride, rising HDL-C/TC ratio, the formation that delays and alleviate atheromatous plaque.In addition, the Radix Polygoni Multiflori stilbene glucoside can also reduce the content of free serum fatty acid and liver lipid peroxide, thereby reduces the liver accumulation of lipid, prevention and treatment fatty liver, liver function protecting.
Cortex Cinnamomi is dried bark, the branch skin in canella Cortex Cinnamomi and osmanthus, Da Ye Qinghua, hot, sweet, the big heat of its nature and flavor, and it is fiery supporing yang to have benefit, dispersing cold for relieving pain, effects such as promoting blood circulation to restore menstrual flow.Modern pharmacological research shows that Cortex Cinnamomi can make triacylglycerol, low density lipoprotein, LDL, total cholesterol level obviously descend.But cinnamic aldehyde-A hypercholesterolemia reducing, triacylglycerol level, rising serum high-density LP content, thereby the effect of performance blood lipid regulation, clinical prevention and the treatment hyperlipemia of being used for.
Following embodiment is used to illustrate the preparation of medicine of the present invention, but it can not constitute any restriction to scope of the present invention.
Embodiment 1
The preparation of drug powder of the present invention:
Prescription: Radix Notoginseng 6g, Radix Puerariae 3g, Semen Cassiae 4g, Radix Polygoni Multiflori 6g, Cortex Cinnamomi 1g
Method for preparing:
Take by weighing in proportion and select clean above-mentioned medical material, common crushing screening, packing gets final product.
Embodiment 2
The preparation of bolus of drug of the present invention:
Prescription: Radix Notoginseng 12g, Radix Puerariae 8g, Semen Cassiae 7g, Radix Polygoni Multiflori 12g, Cortex Cinnamomi 2g
Method for preparing:
Take by weighing in proportion and select clean above-mentioned medical material, common crushing screening, water is general to get final product for ball.
Embodiment 3
The preparation of medicine capsule of the present invention:
Prescription: Radix Notoginseng 12g, Radix Puerariae 6g, Semen Cassiae 6g, Radix Polygoni Multiflori 12g, Cortex Cinnamomi 2g
Method for preparing:
Take by weighing in proportion and select clean above-mentioned medical material, common crushing screening adds gelatinized corn starch and processes suitable granule, and granulations of sieving dried, and the granulate that sieves incapsulates and gets final product.
Embodiment 4
The preparation of medicinal tablet of the present invention:
Prescription: Radix Notoginseng 15g, Radix Puerariae 8g, Semen Cassiae 8g, Radix Polygoni Multiflori 12g, Cortex Cinnamomi 2g
Method for preparing:
Take by weighing in proportion and select clean above-mentioned medical material, common crushing screening adds the carboxylic propyl methocel and processes suitable granule, the granulation of sieving, and oven dry, the granulate that sieves, tabletting gets final product.
Embodiment 5
The preparation of medicinal granule of the present invention:
Prescription: Radix Notoginseng 15g, Radix Puerariae 9g, Semen Cassiae 9g, Radix Polygoni Multiflori 12g, Cortex Cinnamomi 4g
Method for preparing:
Take by weighing in proportion and select clean above-mentioned medical material, common crushing screening is used ethanol percolation, and the percolation clear paste concentrates to be recycled to does not have the alcohol flavor, and dried cream is processed in oven dry, and crushing screening adds sucrose, processes soft material with suitable quantity of water, the granulation of sieving, and oven dry, the granulate that sieves, packing gets final product.
Embodiment 6
The preparation of medicine oral liquid of the present invention:
Prescription: Radix Notoginseng 12g, Radix Puerariae 8g, Semen Cassiae 8g, Radix Polygoni Multiflori 12g, Cortex Cinnamomi 4g
Method for preparing:
Take by weighing in proportion and select clean above-mentioned medical material, common crushing screening use ethanol percolation, and the percolation clear paste concentrates to be recycled to does not have the alcohol flavor, adds water and regulates suitable density, and the granulation of sieving is dried, and the granulate that sieves incapsulates and gets final product.
Embodiment 7
The preparation of medicine decoction of the present invention:
Prescription: Radix Notoginseng 15g, Radix Puerariae 10g, Semen Cassiae 10g, Radix Polygoni Multiflori 12g, Cortex Cinnamomi 5g
Method for preparing:
Above-mentioned medical material is fried by conventional decoction.
Experimental example
Be to confirm medicament adjusting blood fat of the present invention, the good action of treatment hyperlipemia prepares decoction (below be called medicine of the present invention) according to instance 1 said method, and carries out following clinical trial with it.
1 data and method
1.1 case is selected
Select outpatient service or inpatient's 120 examples at random in attached river shore hospital of Jiangsu University, be divided into two groups at random.60 examples are organized in treatment, male's 28 examples, women's 32 examples; 30 ~ 79 years old age; The course of disease is the shortest 1.5 years, and is the longest 15 years; Matched group 60 examples, male's 29 examples, women's 31 examples; 30 ~ 76 years old age; The course of disease is the shortest 0.5 year, and is the longest 15.7.Two groups of sexes, age, the course of disease have comparability through statistical procedures no difference of science of statistics (P>0.05).
1.2 diagnostic criteria
" the adult Chinese dyslipidemia guideline of prevention and treatment " that the Western medicine diagnose standard reference is delivered in May, 2007 formulated; The formulation of tcm diagnosis standard reference State Administration of Traditional Chinese Medicine's " traditional Chinese medical science disease diagnosis criterion of therapeutical effect " in 1994.
1.3 the standard of including in
(1) meet Western medicine diagnose standard and tcm syndrome diagnostic criteria, the age, the men and women all could between 30～75 years old.(2) Primary hyperlipemia: serum total cholesterol (TC)>=6.22 mmol/L (240 mg/dl) (hypercholesterolemia) or serum levels of triglyceride (TG)>=2.26 mmol/L (200mg/dl) (hypertriglyceridemia) or serum high-density LP cholesterol (HDL-C)
<l.04 L (40mg/dl) (low-density lipoprotein leukemia).(3) more than 2 weeks of fat-reducing medicament drug withdrawal, and blood lipid level meets the standard of including in.
1.4 exclusion standard
(1) gestation or women breast-feeding their children, allergic constitution reaches this medicine allergy sufferers.(2) once suffered from patient behind acute myocardial infarction, cerebrovascular accident, severe trauma or the capital operation in half a year.(3) Secondary cases hyperlipemia person is like the hyperlipemia due to nephrotic syndrome, thyroid function attenuating, gout, acute or chronic hepatopathy, the diabetes.(4) hyperlipemia and the homozygous hypercholesterolemiapatients patients that cause by medicine (phenothiazines, beta-Blocking agent, adrenocortical steroid and some contraceptive etc.).(5) use heparin, thyroxine therapy or other to influence the patient of blood lipid metabolism medicine, and nearly two weeks once adopting other to fall the patient of measure.(6) merge liver, kidney, hemopoietic system serious disease, psychosis.(7) can not adhere to treatment, the person of dropping by the wayside.
1.5 Therapeutic Method
The treatment group: use medicine of the present invention (hospital preparation chamber, shore, the attached river of Jiangsu University provides), divide sooner or later and take for 2 times 1 dose of every day, 30 days is 1 course of treatment, treats 3 courses of treatment.Matched group: oral zhibituo capsule (production of Chengdu buchu pharmaceutical Co. Ltd), each 1, take every day 2 times, 30 days is 1 course of treatment, treats 3 courses of treatment.
1.6 observation item
Safety observation: checked respectively the same day with off-test before the treatment: (1) blood, urine, just conventional; (2) heart, liver, renal function.And the untoward reaction that possibly occur in the therapeutic process observed, comprise clinical symptoms, sign, lab testing and the order of severity of observing untoward reaction.Record process and method are with its safety of objective evaluation.
Health giving quality observation: (1) main related symptoms and sign.(2) body weight (1 time weekly).(3) biochemical analysis: the content of serum total cholesterol (TC), triacylglycerol (TG), high density lipoprotein (HDL-C), low-density albumen (LDL-C).
1.8 curative effect determinate standard
With reference to State Administration of Traditional Chinese Medicine's " traditional Chinese medical science disease criterion of therapeutical effect " in 1994, " new Chinese medicine clinical research guideline " hyperlipemia relevant criterion in 2002 and tcm syndrome quantitative criteria were estimated.
The tcm syndrome curative effect determinate standard
(1) clinic control: clinical symptoms, sign disappear or basic the disappearance, and the syndrome integration reduces >=95%.(2) produce effects: clinical symptoms, sign are obviously improved, and the syndrome integration reduces >=70%.(3) effective: clinical symptoms, sign all take a favorable turn, and the syndrome integration reduces >=30%.(4) invalid: clinical symptoms, sign do not have obvious improvement, even increase the weight of, and the syndrome integration reduces less than 30%.Therapeutic index=[integration before (integration before the treatment-treatment back integration) ÷ treatment] * 100% is represented with percent.
The lab testing curative effect determinate standard
(1) clinic control: the inspection of laboratory each item recovers normal.(2) produce effects: lipids detection reaches following each person.TC descends >=20%; TG descends >=40%; HDL-C rising >=0.26mmol/L (10mg/dl); TC-HDL-C/HDL-C descends >=20%.(3) effective: lipids detection reaches following each person.TC descend >=10% but＜20%; TG descend >=20% but＜40%; HDL-C rising >=0.104mmol/L (4mg/dl) but＜0.26mmol/L (10mg/dl); TC-HDL-C/HDL-C descend >=10% but＜20%.(4) invalid: lipids detection does not reach above index.
1.9 statistical procedures
Adopt the SAS13.0 statistical software to carry out statistical analysis.Measurement data adopts (mean ± standard deviation) to carry out descriptive statistics; Compare with baseline, adopt paired t-test or signed rank sum test; Enumeration data adopts frequency (constituent ratio), percent to carry out descriptive statistics.Relatively adopt t check or Wilcoxon rank test between test group and matched group, all statistical test all adopt two-sided test, and < 0.05 has statistical significance for difference to P.
2 results
2.1 the comparison of two groups of case treatment front and back traditional Chinese medical science disease total marks
The own control integrations all significantly reduce (P＜0.01) before and after the treatment of two groups of cases, between the group of treatment back significant difference (P＜0.01) are arranged relatively, show that two groups of cases treatment back diseases all obviously improve, and the treatment group is superior to matched group, see table 1.
The comparison of traditional Chinese medical science disease total mark before and after the table 1 liang group case treatment (`x ± s)
| Group | n | Before the treatment | After the treatment |
| The treatment group | 60 | 14.62±2.94 | 3.32±1.25 ﹡△ |
| Matched group | 60 | 15.57±3.45 | 7.76±3.19 ﹡ |
Relatively preceding with treatment:
﹡P<0.01; Compare between the group of treatment back:
△P<0.01
2.2 the curative effect of two groups of case treatment front and back traditional Chinese medical science diseases relatively
Between the group of two groups of cases treatment back significant difference (P＜0.01) is arranged relatively, show that the treatment group improves the curative effect of traditional Chinese medical science disease and be superior to matched group, see table 2.
The curative effect of traditional Chinese medical science disease relatively before and after the table 2 liang group case treatment
Compare between the group of treatment back:
△P<0.01
2.3 improving the curative effect of blood fat before and after two groups of cases are treated compares
There was no significant difference (P＞0.05) relatively between the group of two groups of cases treatment back shows that two groups all have a curative effect preferably what improve lipid aspects, see table 3.
The curative effect of blood fat and improving relatively before and after the table 3 liang group case treatment
2.4 lipids contents mutation analysis before and after two groups of case treatments
The result shows that treatment group and matched group all can reduce the serum content of TC, TG, LDL-C, and the curative effect of self treatment front and back blood fat and improving more all has significant difference (P < 0.01); Though the serum content of the two groups of HDL-C in treatment back raises to some extent, respectively organize the curative effect of self treating the front and back blood fat and improving and compare there was no significant difference (P＞0.05).The treatment group is compared there was no significant difference (P＞0.05) reducing aspect serum TC content, the elevating HDL-C content with matched group; The treatment group compares and to have significant difference (P < 0.05) reducing aspect serum TG and the LDL-C content with matched group, curative effect is superior to matched group.
Blood lipid level variation before and after the table 4 liang group treatment (`x ± s)
Relatively preceding with treatment:
﹡P<0.01; Compare between the group of treatment back:
▲P<0.05
2.5 safety analysis
In the clinical research process, adverse events does not take place and untoward reaction occurs.
3 conclusions
This invention Drug therapy hyperlipemia determined curative effect, and can significantly alleviate clinical symptoms and sign, do not see tangible untoward reaction, have good potential applicability in clinical practice and promotional value.
Claims (9)
1. herbal mixture medicine of treating hyperlipemia is characterized in that being processed by the crude drug of following parts by weight:
Radix Notoginseng 6-15 part; Radix Puerariae 3-10 part; Semen Cassiae 3-10 part; Radix Polygoni Multiflori 6-12 part; Cortex Cinnamomi 1-5 part.
2. a kind of herbal mixture medicine of treating hyperlipemia according to claim 1 is characterized in that being processed by the crude drug of following parts by weight:
Radix Notoginseng 6-12 part; Radix Puerariae 3-8 part; Semen Cassiae 4-7 part; Radix Polygoni Multiflori 6-12 part; Cortex Cinnamomi 1-2 part.
3. a kind of herbal mixture medicine of treating hyperlipemia according to claim 2 is characterized in that being processed by the crude drug of following parts by weight:
5 parts of Radix Notoginseng 10 Radix Puerariaes; 5 parts of Semen Cassiaes; 10 parts of Radix Polygoni Multiflori; 1 part of Cortex Cinnamomi.
4. a kind of herbal mixture medicine of treating hyperlipemia according to claim 2 is characterized in that being processed by the crude drug of following parts by weight:
6 parts of Radix Notoginseng 10 Radix Puerariaes; 6 parts of Semen Cassiaes; 10 parts of Radix Polygoni Multiflori; 1 part of Cortex Cinnamomi.
5. a kind of herbal mixture medicine of treating hyperlipemia according to claim 2 is characterized in that being processed by the crude drug of following parts by weight:
6 parts of Radix Notoginseng 12 Radix Puerariaes; 6 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 2 parts of Cortex Cinnamomis.
6. a kind of herbal mixture medicine of treating hyperlipemia according to claim 2 is characterized in that being processed by the crude drug of following parts by weight:
8 parts of Radix Notoginseng 15 Radix Puerariaes; 8 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 2 parts of Cortex Cinnamomis.
7. a kind of herbal mixture medicine of treating hyperlipemia according to claim 2 is characterized in that being processed by the crude drug of following parts by weight:
9 parts of Radix Notoginseng 15 Radix Puerariaes; 9 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 4 parts of Cortex Cinnamomis.
8. a kind of herbal mixture medicine of treating hyperlipemia according to claim 2 is characterized in that being processed by the crude drug of following parts by weight:
8 parts of Radix Notoginseng 12 Radix Puerariaes; 8 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 4 parts of Cortex Cinnamomis.
9. a kind of herbal mixture medicine of treating hyperlipemia according to claim 2 is characterized in that being processed by the crude drug of following parts by weight:
15 parts of Radix Notoginseng; 10 parts of Radix Puerariaes; 10 parts of Semen Cassiaes; 12 parts of Radix Polygoni Multiflori; 5 parts of Cortex Cinnamomis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102090573A CN102743448A (en) | 2012-06-25 | 2012-06-25 | Compound traditional Chinese medicine for treating hyperlipidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102090573A CN102743448A (en) | 2012-06-25 | 2012-06-25 | Compound traditional Chinese medicine for treating hyperlipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102743448A true CN102743448A (en) | 2012-10-24 |
Family
ID=47024178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102090573A Pending CN102743448A (en) | 2012-06-25 | 2012-06-25 | Compound traditional Chinese medicine for treating hyperlipidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102743448A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101837104A (en) * | 2009-03-20 | 2010-09-22 | 吴卫兵 | Fat optimizing capsules |
-
2012
- 2012-06-25 CN CN2012102090573A patent/CN102743448A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101837104A (en) * | 2009-03-20 | 2010-09-22 | 吴卫兵 | Fat optimizing capsules |
Non-Patent Citations (2)
| Title |
|---|
| 何岚等: "中药肉桂降血糖、降血脂作用的研究进展", 《中国现代中药》 * |
| 彭悦: "国内降血脂中草药研究概况", 《中药通报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101716242B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN101406688B (en) | Compound formulation for treating rheumatic arthritis and rheumatoid arthritis | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN102726557A (en) | Food possessing auxiliary hypolipidemic function | |
| CN103989996B (en) | It is a kind of to treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN1099835C (en) | Antilipemic beverage or tea | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101116686A (en) | Medicine for treating fatness and its complication | |
| CN102743448A (en) | Compound traditional Chinese medicine for treating hyperlipidemia | |
| CN106617053A (en) | Healthcare food for preventing and treating prostatitis and prostatic hyperplasia and preparation method thereof | |
| CN113274471A (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN101850031B (en) | Pueraria isoflavone capsule | |
| CN104998087A (en) | Traditional Chinese medicine composition for treating primary hypertension and preparing method of traditional Chinese medicine composition | |
| CN109999076A (en) | It is a kind of adjust reverse cholesterol transport Chinese medicine composition and its application | |
| CN104324134A (en) | Traditional Chinese medicine composition for improving microcirculation and preparation method of traditional Chinese medicine composition | |
| CN103525640A (en) | Energy-keeping yang-tonifying wine | |
| CN115120691B (en) | Traditional Chinese medicine composition for improving qi deficiency and blood stasis type perioperative immune microenvironment and life quality of breast cancer and application thereof | |
| CN115252700B (en) | Traditional Chinese medicine composition and medicine for treating cervical tinnitus and preparation method thereof | |
| CN116440224B (en) | Traditional Chinese medicine composition, preparation and preparation method | |
| CN109419844B (en) | Tibetan medicine composition for treating osteoarthritis pain | |
| CN100571722C (en) | Treatment is suffered from a deficiency of the kidney and the pharmaceutical composition of climacteric syndrome and preparation method thereof | |
| CN100569252C (en) | The medicine and the preparation method of treatment essential hypertension | |
| CN107496516B (en) | Composition for treating insomnia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121024 |